Read by QxMD icon Read

Metastasic bladder cancer

Feras Abu Saadeh, Ciaran O Riain, Ciara Mc Cormack, Noreen Gleeson
Uterine leiomyomas are the most common benign gynaecological tumours. However, 0.13 to 6% of them have malignant potential (Robboy et al. Environ Health Perspect 108(Suppl 5):779-784, 2000). Uterine smooth muscle tumours with unusual growth patterns include a spectrum of lesions such as intravenous leiomyomatosis, benign metastasizing leiomyoma and disseminated peritoneal leiomyomatosis (Vaquero et al. J Minim Invasive Gynecol 16:263-268, 2009). Benign metastasizing leiomyoma (BML) is a very rare condition with around 100 cases reported to date...
August 3, 2018: Irish Journal of Medical Science
Kazutaka Kida, Yousuke Shimizu, Kosuke Ogawa, Sojun Kanamaru, Noriyuki Ito
Distant metastasis is rare in patients with non-muscle invasive bladder cancer (NMIBC). We describe two cases of NMIBC with distant metastasis diagnosed in the follow-up period after transurethral resection (TUR), with neither intravesical recurrence nor progression to muscle-invasive disease. Case 1 : A 77-yearold man was referred to our hospital for treatment of a bladder tumor with the complaint of asymptomatic gross hematuria. TUR of the bladder tumor was performed. Pathological examination revealed high grade urothelial carcinoma pT1...
June 2018: Hinyokika Kiyo. Acta Urologica Japonica
Günter Niegisch, Alessandro Nini, René Michalski, Alina Henn, David Mally, Peter Albers, Robert Rabenalt
BACKGROUND: Data on oncological follow-up after robotic-assisted radical cystectomy (RARC) have been reported only scarcely and individual studies have reported an increase in early recurrences and atypical recurrences. PATIENTS AND METHODS: Clinical data of 89 patients with RARC were compared to 59 patients with open radical cystectomy (ORC) at a single institution. Two-year cancer-specific (2y-CSS) and 2-year overall survival (2y-OS) related to histopathological tumor stage of RARC patients calculated by Kaplan-Meier method were compared to ORC patients using log-rank test...
July 25, 2018: Urologia Internationalis
Joep J de Jong, Hans Stoop, Daan Nieboer, Joost L Boormans, Geert J L H van Leenders
AIMS: Programmed Death-Ligand (PD-L1) expression has predictive value for response to immune-checkpoint inhibitor treatment in urothelial cancer patients. The consistency of PD-L1 expression amongst different specimen types is however unknown. The aim of the study is to compare PD-L1 expression in matched transurethral resections of the bladder (TURB), cystectomy specimens, and lymph node metastases of urothelial cancer patients. METHODS AND RESULTS: We performed PD-L1 (SP142) immunohistochemistry on whole tissue slides of 115 urothelial carcinoma patients who had undergone TURB, followed by radical cystectomy and/or pelvic lymph node dissection...
July 12, 2018: Histopathology
Kimiyasu Yoneyama, Motohito Nakagawa, Asuka Hara
BACKGROUND: Breast cancer frequently metastasizes to the bone, lung, and liver. However, metastasis to the bladder is uncommon. Bladder metastasis due to direct infiltration from peripheral organs, such as the colon and rectum, prostate, and cervix, occurs more frequently than metastasis from distant organs, such as the breast. CASE PRESENTATION: We report a case of bladder metastasis identified during treatment for recurrent breast cancer. Fifteen years after her initial surgery, a known breast cancer patient complained of a left lower abdominal pain, anuria, and body swelling...
July 9, 2018: Surgical Case Reports
Mohamed Wishahi, Heba Khalil, Mohamed H Badawy, Amr Elkholy, Khaled Eseily, Shady Anis, Samir Eldahshan, Noura Kamel, Mahmoud Romeih
BACKGROUND: Twist2 is a transcription factor and an epithelial-to-mesenchymal transition that plays an important role in cell polarity, cell adhesion, and has a role in tumour invasion and metastases. AIM: In this study, we examined the expression of Twist2 in non-muscle invasive bladder carcinoma (NMIBC) and correlated the expression with response to treatment and tumour progression. METHODS: Data of 305 patients with NMIBC of Ta, T1 were retrieved from hospitals archives...
June 20, 2018: Open Access Macedonian Journal of Medical Sciences
Gottfrid Sjödahl, Pontus Eriksson, Kristina Lövgren, Nour-Al-Dain Marzouka, Carina Bernardo, Iver Nordentoft, Lars Dyrskjøt, Fredrik Liedberg, Mattias Höglund
Molecular subtypes of muscle-invasive bladder tumors have emerged as a promising research tool with potential to stratify patients for neoadjuvant treatment. Prior to radical cystectomy, the utility of molecular classification and biomarkers depend on concordance between tissue from transurethrally resected specimens and disseminated disease. We assess the concordance of molecular subtypes and a large number of potential biomarkers in 67 pairs of muscle-invasive bladder tumors and synchronous lymph-node metastases...
July 2, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
K Hosny, A Luk
Schistosoma haematobium is the species primarily responsible for the manifestation of schistosomiasis in the genitourinary tract. It is a parasitic disease caused by flukes (trematodes) of the genus Schistosoma, which can result in acute and chronic manifestation. We report a case of urinary schistosomiasis that initially presented as advanced bladder cancer with pulmonary metastasis on initial computed tomography scan. Further investigations revealed no cancer and pulmonary changes resolved with treatment...
July 2018: Annals of the Royal College of Surgeons of England
Adam M Kase, David Menke, Winston Tan
Given the prevalence of breast cancer and the mortality associated with metastatic disease, it is imperative for physicians to not only be aware of common sites but also of rare metastatic destinations such as the bladder. A postmenopausal woman with a medical history of stage 2 invasive ductal carcinoma, oestrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2 negative, in remission for 9 years, presented to her primary care physician with concerns of increased urinary urgency, frequency and incontinence...
June 28, 2018: BMJ Case Reports
Melissa Schwartz, Somali C Gavane, Jad Bou-Ayache, Valentin Kolev, Konstantin Zakashansky, Monica Prasad-Hayes, Bachir Taouli, Linus Chuang, Lale Kostakoglu
PURPOSE: The purpose of the study was to assess the feasibility and diagnostic performance of FDG-PET/MR imaging compared to PET/CT for staging of patients with a gynecological malignancy. METHODS: 25 patients with a gynecological malignancy were prospectively enrolled into this pilot study. Patients underwent sequential full-body PET/CT and PET/MR of the abdomen and pelvis after administration of a single dose of F-18 FDG. PET/MRI and PET/CT images were independently reviewed by two expert radiologists...
June 12, 2018: Abdominal Radiology
Yanan Sun, Fangyan Jiang, Yuemei Pan, Xinming Chen, Jirong Chen, Yu Wang, Xueqing Zheng, Jiali Zhang
X‑box‑binding protein 1 (XBP1) contributes to various types of cancer including breast, bladder cancer and esophageal squamous cell carcinoma. The aim of the study was to examine the metastatic role of XBP1 in oral squamous cell carcinoma (OSCC), and identify possible downstream molecules. Immunohistochemical staining was conducted on tissue microarrays comprising 96 OSCC cases to determine the expression level of XBP1 and analyze its association with metastasis, clinicopathological characteristics and survival prognosis...
August 2018: Oncology Reports
Alessia Cimadamore, Silvia Gasparrini, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Nicola Battelli, Francesco Massari, Francesca Giunchi, Michelangelo Fiorentino, Marina Scarpelli, Rodolfo Montironi
Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses...
June 29, 2018: Expert Review of Molecular Diagnostics
Yu G Alyaev, L M Rapoport, A Z Vinarov, N I Sorokin, A M Dymov, D A Kislyakov, E V Afanasyevskaya, V Yu Lekarev
Currently, transurethral resection of a bladder tumor (TUR) is the gold standart treatment for non-muscle invasive bladder cancer (NMIBC). Standard TUR for a bladder wall tumor has a high recurrence rate, which is caused mainly by malignant cell implantation during the surgery. Besides, specimens obtained with conventional TUR are insufficient for accurate pathological staging. The non-conformity of the standard TUR with the established oncological principle of dissecting through normal tissue prompted a search for the optimal surgical modality...
May 2018: Urologii︠a︡
Mohammad Amin Hosseini, Mohammad Mohamadianpanah, Mohammad Zare-Bandeamiri, Mohammad Amin Mosleh-Shirazi
Hadron therapy (HT) with protons and carbon ions is an advanced radiotherapy technique. As the first report addressing this topic, the present study aimed to estimate the number of patients eligible for HT in Fars province and the whole of Iran. The data were collected through direct inspection of medical records of the patients treated at the Radiotherapy Department, Namazi Hospital, Shiraz, Iran in 2014. The patients who were treated with external-beam radiotherapy and declared to be a resident of Fars province were extracted from the medical records...
May 2018: Iranian Journal of Medical Sciences
Anja Rabien, Nadine Ratert, Anica Högner, Andreas Erbersdobler, Klaus Jung, Thorsten H Ecke, Ergin Kilic
Bladder cancer still requires improvements in diagnosis and prognosis, because many of the cases will recur and/or metastasize with bad outcomes. Despite ongoing research on bladder biomarkers, the clinicopathological impact and diagnostic function of miRNA maturation regulators Drosha and Argonaute proteins AGO1 and AGO2 in urothelial bladder carcinoma remain unclear. Therefore, we conducted immunohistochemical investigations of a tissue microarray composed of 112 urothelial bladder carcinomas from therapy-naïve patients who underwent radical cystectomy or transurethral resection and compared the staining signal with adjacent normal bladder tissue...
May 31, 2018: International Journal of Molecular Sciences
Jill B Feffer, Natalia M Branis, Jeanine B Albu
Objective: Extrapulmonary small cell carcinoma (EPSCC) is rare and frequent metastases at presentation can complicate efforts to identify a site of origin. In particular, SCC comprises <1% of prostate cancers and has been implicated in castration resistance. Methods: Clinical, laboratory, imaging, and pathology data are presented. Results: A 56-year-old man with locally advanced prostate adenocarcinoma on androgen deprivation therapy presented with a clogged nephrostomy tube...
2018: Frontiers in Endocrinology
Christian B van der Pol, V Anik Sahni, Steven C Eberhardt, Aytekin Oto, Oguz Akin, Lauren F Alexander, Brian C Allen, Fergus V Coakley, Adam T Froemming, Pat F Fulgham, Keyanoosh Hosseinzadeh, Jodi K Maranchie, Rekha N Mody, Nicola Schieda, David M Schuster, Aradhana M Venkatesan, Carolyn L Wang, Mark E Lockhart
Muscle-invasive bladder cancer (MIBC) has a tendency toward urothelial multifocality and is at risk for local and distant spread, most commonly to the lymph nodes, bone, lung, liver, and peritoneum. Pretreatment staging of MIBC should include imaging of the urothelial upper tract for synchronous lesions; imaging of the chest, abdomen, and pelvis for metastases; and MRI pelvis for local staging. CT abdomen and pelvis without and with contrast (CT urogram) is recommended to assess the urothelium and abdominopelvic organs...
May 2018: Journal of the American College of Radiology: JACR
Peter Rexin, Alessa Tauchert, Jörg Hänze, Hendrik Heers, Ansgar Schmidt, Rainer Hofmann, Axel Hegele
BACKGROUND: We examined the expression of CD200, a ligand of immune tolerance, in transitional cell carcinoma of the human bladder (TCC). MATERIALS AND METHODS: CD200 was analyzed by immunohistochemistry (IHC) in 90 patients with suspected TCC lesions of the bladder. Expression of CD200 was exemplarily validated by quantitative reverse transcription polymerase chain reaction and western blot analysis. RESULTS: CD200 was detectable at mRNA and protein levels in TCC homogenate and TCC cell lines (T24, UMUC3)...
May 2018: Anticancer Research
James M Taylor, Emory R McTyre, Stephen B Tatter, Adrian W Laxton, Michael T Munley, Michael D Chan, Christina K Cramer
BACKGROUND/AIMS: Brain metastases from bladder cancer are rare and published outcomes data are sparse. To date, no institutions have reported a series of patients with brain metastases from bladder cancer treated with stereotactic radiosurgery (SRS). Our aim was to identify patients with brain metastases from bladder primaries treated with SRS with or without surgical resection and report the clinical outcomes. METHODS: Patients meeting eligibility criteria at our institution between 2000 and 2017 were included...
2018: Stereotactic and Functional Neurosurgery
Dirk Rades, Liesa Dziggel, Lisa Manig, Stefan Janssen, Mai Trong Khoa, Vuong Ngoc Duong, Vu Huu Khiem, Steven E Schild
BACKGROUND/AIM: This study aimed to create a predictive tool for estimating the remaining lifespan of patients after whole-brain irradiation (WBI) for cerebral metastases from bladder cancer. PATIENTS AND METHODS: In 34 of these patients clinical parameters were analyzed for survival including age at start of WBI, gender, Karnofsky score, number of cerebral metastases and involvement of extra-cranial sites of metastasis. RESULTS: Involvement of extra-cranial sites (14%) and Karnofsky score (9%) showed the greatest difference regarding 6-month survival and were considered for the tool...
May 2018: In Vivo
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"